Cite
Repurposing of FDA Approved Drugs Against SARS-CoV-2 Papain-Like Protease: Computational, Biochemical, and in vitro Studies
MLA
Rajkumar Kulandaisamy, et al. “Repurposing of FDA Approved Drugs Against SARS-CoV-2 Papain-Like Protease: Computational, Biochemical, and in Vitro Studies.” Frontiers in Microbiology, vol. 13, May 2022. EBSCOhost, https://doi.org/10.3389/fmicb.2022.877813.
APA
Rajkumar Kulandaisamy, Tushar Kushwaha, Anu Dalal, Vikas Kumar, Deepa Singh, Kamal Baswal, Pratibha Sharma, Kokkula Praneeth, Pankaj Jorwal, Sarala R. Kayampeta, Tamanna Sharma, Srinivas Maddur, Manoj Kumar, Saroj Kumar, Aparoy Polamarasetty, Aekagra Singh, Deepak Sehgal, Shivajirao L. Gholap, Mohan B. Appaiahgari, … Krishna K. Inampudi. (2022). Repurposing of FDA Approved Drugs Against SARS-CoV-2 Papain-Like Protease: Computational, Biochemical, and in vitro Studies. Frontiers in Microbiology, 13. https://doi.org/10.3389/fmicb.2022.877813
Chicago
Rajkumar Kulandaisamy, Tushar Kushwaha, Anu Dalal, Vikas Kumar, Deepa Singh, Kamal Baswal, Pratibha Sharma, et al. 2022. “Repurposing of FDA Approved Drugs Against SARS-CoV-2 Papain-Like Protease: Computational, Biochemical, and in Vitro Studies.” Frontiers in Microbiology 13 (May). doi:10.3389/fmicb.2022.877813.